Tango Therapeutics has dosed the first patient in its Phase I/II trial of TNG462 to treat patients with methylthioadenosine phosphorylase (MTAP) deleted solid tumours.
The study will assess the efficacy, safety, pharmacokinetics and pharmacodynamics of methylthioadenosine (MTA)-cooperative PRMT5 inhibitor TNG462 in MTAP-deleted solid tumours, including non-small cell lung cancer, mesothelioma and cholangiocarcinoma.
Go deeper with GlobalData
Tango Therapeutics president and CEO Barbara Weber said: “Dosing the first patient with our next-generation MTA-cooperative PRMT5 inhibitor, TNG462, demonstrates our deep commitment to developing transformative treatments for patients with MTAP-deleted cancers.
“MTAP deletions occur in 10%-15% of solid tumours, including many with limited treatment options, and there currently are no FDA-approved treatments specifically for cancers with MTAP deletion.
“TNG908, our brain-penetrant MTA-cooperative PRMT5 inhibitor, also is being evaluated in an ongoing Phase I/II study. Each molecule has unique properties, and by advancing both programmes, we have the opportunity to make a difference in a broader range of indications.”
TNG462 exhibits the same mechanism of action as TNG908 while the former has enhanced potency and selectivity.
TNG462 is 45X selective for MTAP deletions (three-fold greater than TNG908) and 20 times more potent than TNG908.
TNG908 was granted orphan drug designation in the US for treating malignant glioma. It has shown efficacy in both subcutaneous and orthotopic MTAP-null glioblastoma xenograft models.
A clinical-stage biotechnology company, Tango Therapeutics is involved in discovering new drug targets and delivers precision medicine for cancer treatment.
